Evaluation of antimicrobial susceptibility of Escherichia coli strains isolated in Rabat University Hospital (Morocco)

BMC Research Notes

Mostafa Elouennass³  Abdelhay Lemnouer³  Azzedine Ibrahimi³  Lhoucin Louzi³  Yassine Sekhsokh³  Mariama Chadli³  Adil Maleb¹  Abdellatif Srifi³  Mohammed Frikh³  Nabil Alem² 

[1] Faculté de Médecine de Pharmacie d’Oujda Université Mohammed I, Oujda, Morocco;villa 96 la corniche hay el fath, Rabat, Morocco;Faculté de Médicine et de Pharmacie de Rabat Université Mohammed V Souissi, Rabat, Morocco

关键词: Morocco;    Antimicrobial susceptibility;    Escherichia coli;   

Others  :  1230434
DOI  :  10.1186/s13104-015-1380-9

 received in 2014-04-21, accepted in 2015-08-24,  发布年份 2015

【 摘 要 】

Background

Escherichia coli (E. coli) is the most commonly isolated bacteria in human pathology. In Morocco the data concerning the nature and the rates of antibiotic resistance of E. coli in both hospitals and city environment remains relatively poor and needs further investigations.

Methods

During a 16 months period, E. coli isolates were collected from different culture specimens received in the Bacteriology Department of the Military teaching Hospital Mohammed-V-Rabat for routine diagnostic purposes. E. coli isolates were identified and their antimicrobial susceptibility pattern was determined.

Results

A total of 1369 E. coli isolates comprising 33 % (1369/4110) of culture-positive samples were consecutively collected. Isolates of E. coli were, in 40.5 % (554/1369) of cases from hospitalized patients and in 59.5 % (815/1369) of cases from outpatients. Urine isolates represented 82 % (1123/1369) of the cases. High rates of resistance were found for amoxicillin (42.5 %), cefalotin (30.4 %), norfoloxacin (29.9 %) and sulfamethoxazole (37.7 %). The detection rate of ESBL was 6.1 % (85/1369). In hospitalized patients 11.9 % of the isolates of E. coli (66/554) had an ESBL phenotype while in outpatients cases only 2.3 % of isolates of E. coli (19/815) had this phenotype.

Conclusions

Our findings suggest that more judicious use of antibiotics is needed especially in probabilistic treatment. The emergence of ESBL in the Moroccan cities is an indicator of the severity of this problem that is not limited to health care facilities.

【 授权许可】

   
2015 Alem et al.

【 参考文献 】

• [1]Lobel B, Valot A, Cattoir V, Lemenand O, Gaillot O: Comparison of antimicrobial susceptibility of 1,217 Escherichia coli isolates from women with hospital and community-acquired urinary tract infections. Presse Med. 2008, 37(5 Pt 1):746-750.
• [2]De Francesco MA, Ravizzola G, Peroni L, Negrini R, Manca N. Urinary tract infections in Brescia, Italy: etiology of uropathogens and antimicrobial resistance of common uropathogens. Med Sci Monit. 2007;13(6):BR136–44.
• [3]Kashef N, Djavid GE, Shahbazi S: Antimicrobial susceptibility patterns of community-acquired uropathogens in Tehran, Iran. J Infect Dev Ctries 2010, 4(4):202-206.
• [4]Wagenlehner FM, Naber KG, Weidner W: Rational antibiotic therapy of urinary tract infections. Med Monatsschr Pharm. 2008, 31(10):385-390.
• [5]Biedenbach DJ, Moet GJ, Jones RN: Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002). Diagn Microbiol Infect Dis 2004, 50(1):59-69.
• [6]Naheed AK, Noor US, Abdus S, Ali Abbas Q: Incidence and antibiogram patterns of Escherichia coli isolated from various clinical samples from patients at N.I.H. Islamabad. Pak J Biol Sci 2002, 5(1):111-113.
• [7]Turner SM, Scott-Tucker A, Cooper LM, Henderson IR: Weapons of mass destruction: virulence factors of the global killer enterotoxigenic Escherichia coli. FEMS Microbiol Lett 2006, 263(1):10-20.
• [8]Ibrahim ME, Bilal NE, Hamid ME: Increased multi-drug resistant Escherichia coli from hospitals in Khartoum state, Sudan. Afr Health Sci 2012, 12(3):368-375.
• [9]Bean DC, Krahe D, Wareham DW: Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005–2006. Ann Clin Microbiol Antimicrob. 2008, 7:13. BioMed Central Full Text
• [10]Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN: Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998–99). Diagn Microbiol Infect Dis 2002, 42(3):193-198.
• [11]El Kholy A, Baseem H, Hall GS, Procop GW, Longworth DL: Antimicrobial resistance in Cairo, Egypt 1999–2000: a survey of five hospitals. J Antimicrob Chemother 2003, 51(3):625-630.
• [12]Soussy JC. Recommandation du Comité de l’antibiogramme de la société française de microbiologie. 2011.
• [13]Chomarat M: Resistance of bacteria in urinary tract infections. Int J Antimicrob Agents 2000, 16(4):483-487.
• [14]Kahlmeter G: An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003, 51(1):69-76.
• [15]L’observatoire national de l’épidemiologie de la resistance aux antibiotiques. 2014.. http://www.onerba.org webcite
• [16]Fabre R, Merens A, Lefebvre F, Epifanoff G, Cerutti F, Pupin H, Tardif D, Cavallo JD, Ternois I: Susceptibility to antibiotics of Escherichia coli isolated from community-acquired urinary tract infections. Med Mal Infect. 2010, 40(10):555-559.
• [17]Tagajdid MR, Boumhil L, Iken M, Adnaoui M, Benouda A: Resistance to fluoroquinolones and third generation cephalosporin of Escherichia coli isolated from urines. Med Mal Infect. 2010, 40(2):70-73.
• [18]El Bouamri MC, Arsalane L, Kamouni Y, Berraha M, Zouhair S. Evolution récente du profil épidémiologique des entérobactéries uropathogènes productrices de blactamases à spectre élargi à Marrakech, Maroc. Progrès en Urologie. 2014;(24):1058–62.
• [19]Abreu AG, Marques SG, Monteiro-Neto V, Goncalves AG: Extended-spectrum beta-lactamase-producing enterobacteriaceae in community-acquired urinary tract infections in Sao Luis, Brazil. Braz J Microbiol. 2013, 44(2):469-471.
• [20]Bourjilat F, Bouchrif B, Dersi N, Claude JD, Amarouch H, Timinouni M: Emergence of extended-spectrum beta-lactamases-producing Escherichia coli in community-acquired urinary infections in Casablanca, Morocco. J Infect Dev Ctries 2011, 5(12):850-855.
• [21]Rodriguez-Bano J, Alcala J, Cisneros JM, Grill F, Oliver A, Horcajada JP, Tortola T, Mirelis B, Navarro G, Cuenca M, et al.: Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection. J Antimicrob Chemother. 2009, 63(4):781-784.
• [22]Yu X, Susa M, Weile J, Knabbe C, Schmid RD, Bachmann TT: Rapid and sensitive detection of fluoroquinolone-resistant Escherichia coli from urine samples using a genotyping DNA microarray. Int J Med Microbiol 2007, 297(6):417-429.
• [23]Ling TK, Xiong J, Yu Y, Lee CC, Ye H, Hawkey PM: Multicenter antimicrobial susceptibility survey of gram-negative bacteria isolated from patients with community-acquired infections in the People’s Republic of China. Antimicrob Agents Chemother 2006, 50(1):374-378.
• [24]Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP: Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003, 289(7):885-888.
• [25]Guessennd N, Bremont S, Gbonon V, Kacou-Ndouba A, Ekaza E, Lambert T, Dosso M, Courvalin P: Qnr-type quinolone resistance in extended-spectrum beta-lactamase producing enterobacteria in Abidjan, Ivory Coast. Pathol Biol (Paris) 2008, 56(7–8):439-446.